Neuroblastoma: evolving therapies for a disease with many faces - PubMed (original) (raw)

Review

Neuroblastoma: evolving therapies for a disease with many faces

Robert E Goldsby et al. Paediatr Drugs. 2004.

Abstract

Neuroblastoma is the most common extra-cranial solid tumor in children and has a heterogeneous clinical presentation and course. Clinical and biologic features of this disease have been used to develop risk-based therapy. Patients with low-risk disease can be treated with surgery alone. Patients with intermediate-risk features have an excellent prognosis after treatment with surgery and a relatively short course of standard dose chemotherapy. Unfortunately, most children with neuroblastoma present with advanced disease. More than 60% of patients with high-risk features will succumb to their disease despite intensive therapy including a myeloablative consolidation. Research efforts to understand the biologic basis of neuroblastoma and to identify new, more effective therapies are essential to improve the outcome for these children.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Med Pediatr Oncol. 2001 Jan;36(1):169-76 - PubMed
    1. Cancer Res. 1995 Dec 1;55(23):5681-6 - PubMed
    1. Science. 1984 Jun 8;224(4653):1121-4 - PubMed
    1. Lancet. 1996 Dec 21-28;348(9043):1682-7 - PubMed
    1. J Clin Oncol. 1998 Apr;16(4):1256-64 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources